Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO GU 2026

26 - 28 Feb 2026

Moscone West, San Francisco, United States of America

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes...

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in...

Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC ( Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan )

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC...

Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival ( Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

Microplastics found at higher levels in prostate cancer tissue compared to...

Dr Stacy Loeb - NYU Langone Health, New York, NY

Microplastics found at higher levels in prostate cancer tissue compared to benign tissue ( Dr Stacy Loeb - NYU Langone Health, New York, NY )

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and...

Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA ( Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA )

Real-world cardiovascular risks with novel hormonal therapies in advanced...

Dr Dalia Kaakour - University of California, Irvine, USA

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer ( Dr Dalia Kaakour - University of California, Irvine, USA )

Circulating tumour DNA shows high accuracy for monitoring testicular cancer...

Dr Dalia Kaakour - University of California, Irvine, USA

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages ( Dr Dalia Kaakour - University of California, Irvine, USA )

First real-world study of penile cancer in Bolivia reveals high HPV-related...

Dr Lucia Richter - Instituto Oncologico del Oriente Boliviano, Santa Cruz De La...

First real-world study of penile cancer in Bolivia reveals high HPV-related rates and advanced disease ( Dr Lucia Richter - Instituto Oncologico del Oriente Boliviano, Santa Cruz De La Sierra, Bolivia )

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis...

Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer ( Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA )

Belzutifan plus palbociclib shows modest activity with manageable safety in...

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced...

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Pembrolizumab plus belzutifan improves disease-free survival in high-risk...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Darolutamide improves progression-free survival across comorbidities in...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

225Ac-PSMA-trillium shows high PSA response and favourable safety in metastatic...

Prof Fred Saad - University of Montreal, Montreal, Canada

225Ac-PSMA-trillium shows high PSA response and favourable safety in metastatic castration-resistant prostate cancer ( Prof Fred Saad - University of Montreal, Montreal, Canada )

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell...

Dr Sophie Merrick - University College London, London, UK

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients ( Dr Sophie Merrick - University College London, London, UK )

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high...

Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The...

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC ( Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands )

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL...

Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC ( Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA )

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease...

Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA

$Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control ( Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA )$

QoL outcomes are inconsistently reported in contemporary phase III...

Dr Shreyas Kalantri - University of Louisville, Louisville

QoL outcomes are inconsistently reported in contemporary phase III genitourinary cancer trials ( Dr Shreyas Kalantri - University of Louisville, Louisville )

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS...

Dr Aly-Khan Lalani - McMaster University, Hamilton, Canada

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS benefit but is safe ( Dr Aly-Khan Lalani - McMaster University, Hamilton, Canada )

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves...

Prof Steffen Rausch - University of Tübingen, Tübingen, Germany

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC ( Prof Steffen Rausch - University of Tübingen, Tübingen, Germany )

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in...

Dr Anna Wilkins - The Institute of Cancer Research, London, UK

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer ( Dr Anna Wilkins - The Institute of Cancer Research, London, UK )

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows...

Dr Karie Runcie - Columbia University, New York, USA

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC ( Dr Karie Runcie - Columbia University, New York, USA )

ASCO GU 2026: Updates in renal cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in renal cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez...

ASCO GU 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez and Dr Guillermo de Velasco )

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )

Evaluation and definition of response and progression from trials to clinical...

Dr Andrew Armstrong - Duke University, Durham, North Carolina

Evaluation and definition of response and progression from trials to clinical practice ( Dr Andrew Armstrong - Duke University, Durham, North Carolina )

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle...

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

More from ecancer